申请人:The General Hospital Corporation
公开号:US20140288174A1
公开(公告)日:2014-09-25
This disclosure relates to inhibitors of the Wni pathway, and compositions comprising the same, as well as to their use in the treatment of disorders characterized by the activation of Writ pathway signaling (e.g., cancer), as well as to the modulation of cellular events mediated by VVnt pathway signaling.